Evidence map›Paper›PMID 26048627›Full record

ArticleTuberculosis (Edinburgh, Scotland)2015

The presence of a galactosamine substituent on the arabinogalactan of Mycobacterium tuberculosis abrogates full maturation of human peripheral blood monocyte-derived dendritic cells and increases secretion of IL-10.

William H Wheat, Rabeb Dhouib, Shiva K Angala, Gérald Larrouy-Maumus, Karen Dobos, Jérôme Nigou, John S Spencer, Mary Jackson

Open access · greenAbstract readComparative Study
In one paragraph

Article in Tuberculosis (Edinburgh, Scotland), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Genes required forbioRxiv : the preprint server for biology · 2025
    Article
  2. Article
  3. Regulatory role ofFrontiers in microbiology · 2024
    Article
  4. Article
  5. Article
  6. Disruption of the SucT acyltransferase inThe Journal of biological chemistry · 2019
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

William H WheatMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA. Electronic address: william.wheat@colostate.edu.
Rabeb DhouibMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.
Shiva K AngalaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.
Gérald Larrouy-MaumusCNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale), Département Mécanismes Moléculaires des Infections Mycobactériennes, 205 route de Narbonne, F-31077 Toulouse, France; Université de Toulouse, UPS, IPBS, F-31077 Toulouse, France.
Karen DobosMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.
Jérôme NigouCNRS, IPBS (Institut de Pharmacologie et de Biologie Structurale), Département Mécanismes Moléculaires des Infections Mycobactériennes, 205 route de Narbonne, F-31077 Toulouse, France; Université de Toulouse, UPS, IPBS, F-31077 Toulouse, France.
John S SpencerMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.
Mary JacksonMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682, USA.
Colorado State University · USCentre National de la Recherche Scientifique · FR

Funding

Biogenesis of Lipoarabinomannan in MycobacteriaR01AI064798 · NIAID · COLORADO STATE UNIVERSITY-FORT COLLINS · PI JACKSON, MARY · 2005 to 2019
$5.4M
Medical Research Council MR/J006874/1NIAID NIH HHS AI064798NIAID NIH HHS R01 AI064798
6 · The paper itself

Abstract

Slow-growing and pathogenic Mycobacterium spp. are characterized by the presence of galactosamine (GalN) that modifies the interior branched arabinosyl residues of the arabinogalactan (AG) that is a major heteropolysaccharide cell wall component. The availability of null mutants of the polyprenyl-phospho-N-acetylgalactosaminyl synthase (Rv3631, PpgS) and the (N-acetyl-) galactosaminyl transferase (Rv3779) of Mycobacterium tuberculosis (Mtb) has provided a means to elucidate the role of the GalN substituent of AG in terms of host-pathogen interactions. Comparisons of treating human peripheral blood monocyte-derived dendritic cells (hPMC-DCs) with wild-type, Rv3631 and Rv3779 mutant strains of Mtb revealed increased expression of DC maturation markers, decreased affinity for a soluble DC-SIGN probe, reduced IL-10 secretion and increased TLR-2-mediated NF-κB activation among GalN-deficient Mtb strains compared to GalN-producing strains. Analysis of surface expression of a panel of defined or putative DC-SIGN ligands on both WT strains or either Rv3631 or Rv3779 mutant did not show significant differences suggesting that the role of the GalN substituent of AG may be to modulate access of the bacilli to immunologically-relevant receptor domains on DCs or contribute to higher ordered pathogen associated molecular pattern (PAMP)/pattern recognition receptor (PRR) interactions rather than the GalN-AG components having a direct immunological effect per se.

Indexed as

Cells, CulturedDendritic CellsGalactansGalactosamineGenotypeHost-Pathogen InteractionsHumansInterleukin-10MutationMycobacterium tuberculosisN-AcetylgalactosaminyltransferasesNF-kappa BPhenotypeToll-Like Receptor 2Up-RegulationarabinogalactanGalactansGalactosamineIL10 protein, humanInterleukin-10N-AcetylgalactosaminyltransferasesNF-kappa BTLR2 protein, humanToll-Like Receptor 2ArabinogalactanCell wallDC-SIGNDendritic cellGalactosamineGalNGalN-AGHost responseHuman PBMCIL-10Innate immunityMycobacteriumMycobacterium tuberculosisPAMPPRR

Identifiers

PMID26048627
PMCPMC4475442
OpenAlexW1683254783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.